SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Among adults with type 2 diabetes, SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases compared with sulfonylureas.
A study published online found that Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes.
Bin Hong, from Sungkyunkwan University in the Republic of Korea, and colleagues examined use of SGLT-2 inhibitors and the risk for autoimmune rheumatic diseases in a retrospective cohort study involving 2,032,157 adults with type 2 diabetes.
The researchers found that the weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.
Author's summary: SGLT-2 inhibitors reduce autoimmune disease risk in T2D adults.
More News
- Why is the Google Doodle Pac-Man themed? | LBC
- Ayuba Sylvester James: “For MCP to Rise, Chakwera Must Fall” - Malawi Nyasa Times - News from Malawi about Malawi
- Legal Expertise Has a Visibility Problem--And It's Costing Top Attorneys Millions
- 10 tracks that prove MF DOOM was the master of samples
- 'Hotel Transylvania' spinoff 'Motel Transylvania' delayed, now set for 2027 release on Netflix | The Express Tribune
- Florence + The Machine - Everybody Scream Review
- 'Thief VR: Legacy of Shadow' Comes to All Major VR Headsets in December, New Gameplay Here
- Spot the Anglican Irony - THE OTHER CHEEK
- Cineworld announces luxury upgrade at Silverburn with new recliner seats
- Sweater Weather: Billboard Crossword (Oct. 30, 2025)